PL364598A1 - Stabilna odmiana polimorficzna flibanseryny, techniczny sposób jej wytwarzania i jej zastosowanie do otrzymywania leków - Google Patents

Stabilna odmiana polimorficzna flibanseryny, techniczny sposób jej wytwarzania i jej zastosowanie do otrzymywania leków

Info

Publication number
PL364598A1
PL364598A1 PL02364598A PL36459802A PL364598A1 PL 364598 A1 PL364598 A1 PL 364598A1 PL 02364598 A PL02364598 A PL 02364598A PL 36459802 A PL36459802 A PL 36459802A PL 364598 A1 PL364598 A1 PL 364598A1
Authority
PL
Poland
Prior art keywords
flibanserin
preparation
technical process
preparing medicaments
stable polymorph
Prior art date
Application number
PL02364598A
Other languages
English (en)
Other versions
PL210224B1 (pl
Inventor
Carlo Bombarda
Enrica Dubini
Antoine Ezhaya
Original Assignee
Bidachem S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bidachem S.P.A. filed Critical Bidachem S.P.A.
Publication of PL364598A1 publication Critical patent/PL364598A1/pl
Publication of PL210224B1 publication Critical patent/PL210224B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PL364598A 2001-08-02 2002-07-30 Krystaliczna odmiana polimorficzna flibanseryny, sposób jej wytwarzania, jej zastosowanie, oraz kompozycje farmaceutyczne ją zawierające PL210224B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01118593 2001-08-02
EP01130180 2001-12-19
PCT/EP2002/008466 WO2003014079A1 (en) 2001-08-02 2002-07-30 Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments

Publications (2)

Publication Number Publication Date
PL364598A1 true PL364598A1 (pl) 2004-12-13
PL210224B1 PL210224B1 (pl) 2011-12-30

Family

ID=26076670

Family Applications (1)

Application Number Title Priority Date Filing Date
PL364598A PL210224B1 (pl) 2001-08-02 2002-07-30 Krystaliczna odmiana polimorficzna flibanseryny, sposób jej wytwarzania, jej zastosowanie, oraz kompozycje farmaceutyczne ją zawierające

Country Status (27)

Country Link
EP (2) EP1518858A1 (pl)
JP (1) JP3822601B2 (pl)
KR (1) KR100899297B1 (pl)
CN (1) CN1288147C (pl)
AR (2) AR036208A1 (pl)
AT (1) ATE288911T1 (pl)
AU (1) AU2002331361B2 (pl)
BR (1) BR0211601A (pl)
CA (1) CA2450093C (pl)
CO (1) CO5560572A2 (pl)
DE (1) DE60202958T2 (pl)
DK (1) DK1414816T3 (pl)
EA (1) EA006400B1 (pl)
ES (1) ES2237694T3 (pl)
HK (1) HK1070063A1 (pl)
HR (1) HRP20040107B1 (pl)
HU (1) HU228666B1 (pl)
IL (2) IL159151A0 (pl)
MX (1) MXPA04000913A (pl)
MY (1) MY127294A (pl)
NZ (1) NZ530510A (pl)
PL (1) PL210224B1 (pl)
PT (1) PT1414816E (pl)
RS (1) RS50742B (pl)
SI (1) SI1414816T1 (pl)
UA (1) UA76767C2 (pl)
WO (1) WO2003014079A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
DE10138273A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
ATE499939T1 (de) * 2002-05-22 2011-03-15 Boehringer Ingelheim Pharma Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
JP2008540356A (ja) * 2005-05-06 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬物乱用の治療方法
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
EP1945214A1 (en) 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
US20090247546A1 (en) * 2006-02-28 2009-10-01 Boehringer Ingelheim International Gmbh Treatment of Prevention of Valvular Heart Disease with Flibanserin
MX2008013827A (es) * 2006-05-09 2008-11-10 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual.
DE602007004615D1 (de) 2006-06-30 2010-03-18 Boehringer Ingelheim Pharma Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
JP5793828B2 (ja) 2006-08-14 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンの製剤及びその製造方法
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
CN101505736A (zh) 2006-08-25 2009-08-12 贝林格尔.英格海姆国际有限公司 控制释放系统及其制造方法
WO2008061966A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim International Gmbh New use of flibanserin
CA2672957C (en) 2006-12-20 2015-04-14 Boehringer Ingelheim International Gmbh Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity
EP1955699A1 (en) * 2007-02-08 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flibanserin for the treatment of insomnia
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
EP2090297A1 (en) 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
CA2686480A1 (en) * 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
WO2017076356A1 (zh) * 2015-11-05 2017-05-11 苏州晶云药物科技有限公司 氟班色林的新晶型及其制备方法
CN113683570A (zh) * 2016-01-31 2021-11-23 孟晓明 氟班色林的新晶型及其制备方法及其用途
CN111303043A (zh) * 2019-04-19 2020-06-19 武汉万知化工医药有限公司 一种氟班色林盐酸盐的制备方法
CN115919860B (zh) * 2022-12-05 2023-11-10 中国药科大学 氟班色林在制备治疗雄激素脱发药物中的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone

Also Published As

Publication number Publication date
EA006400B1 (ru) 2005-12-29
CO5560572A2 (es) 2005-09-30
CA2450093C (en) 2008-09-23
DE60202958T2 (de) 2006-04-06
EP1414816A1 (en) 2004-05-06
IL159151A (en) 2009-09-22
WO2003014079A1 (en) 2003-02-20
CN1551879A (zh) 2004-12-01
JP2004537597A (ja) 2004-12-16
ES2237694T3 (es) 2005-08-01
JP3822601B2 (ja) 2006-09-20
YU7804A (sh) 2006-08-17
KR100899297B1 (ko) 2009-05-26
CA2450093A1 (en) 2003-02-20
KR20040023704A (ko) 2004-03-18
CN1288147C (zh) 2006-12-06
AR077416A2 (es) 2011-08-24
NZ530510A (en) 2004-07-30
DE60202958D1 (de) 2005-03-17
EP1414816B1 (en) 2005-02-09
IL159151A0 (en) 2004-06-01
EP1518858A1 (en) 2005-03-30
HRP20040107B1 (en) 2012-02-29
HU228666B1 (en) 2013-05-28
EA200400252A1 (ru) 2004-08-26
DK1414816T3 (da) 2005-04-11
BR0211601A (pt) 2004-08-24
HUP0401201A2 (hu) 2004-10-28
RS50742B (sr) 2010-08-31
ATE288911T1 (de) 2005-02-15
HRP20040107A2 (en) 2004-06-30
SI1414816T1 (en) 2005-06-30
PL210224B1 (pl) 2011-12-30
UA76767C2 (uk) 2006-09-15
HUP0401201A3 (en) 2004-11-29
MXPA04000913A (es) 2004-10-27
WO2003014079A8 (en) 2003-11-20
HK1070063A1 (en) 2005-06-10
AU2002331361B2 (en) 2008-06-05
PT1414816E (pt) 2005-04-29
MY127294A (en) 2006-11-30
AR036208A1 (es) 2004-08-18

Similar Documents

Publication Publication Date Title
YU7804A (sh) Stabilni polimorf flibanserina,postupak za njegovo dobijanje u industrijskim razmerama i njegova primena za pripremanje lekova
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
GB0013488D0 (en) Chemical compound
MY136430A (en) N-adamantylmethyl derivatives, pharmaceutical compositions containing them and processes for their preparation
MXPA03010201A (es) Derivados de 2-piridin-ciclohexan-1,4-diamina sustituidos.
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
DE60116761D1 (en) Adamantanderivate
JO2493B1 (en) New phenyl azatidinone with improved physical properties and methods of preparation of drugs containing it and its uses
RS98704A (en) New pharmaceutical compositions containing flibanserin polymorpha
GB0109122D0 (en) Novel compounds
BG105197A (en) Polymorph form of a medicament
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
PL373723A1 (pl) Sposób wytwarzania kwasu 1,2-benzizoksazolo-3-octowego
BG106002A (en) Process for preparing pesticidal intermediates
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
WO2001049651A3 (de) Aminomethyl-phenyl-cyclohexanonderivate
PL369718A1 (pl) Sposób wytwarzania pochodnych [1,4,5]-oksadiazepiny
CA2425368A1 (en) New sulphoxybenzamides
MY127328A (en) 5-amino-1-pentene-3-ol substituted derivatives
EP1295864A4 (en) PROCESS FOR THE PREPARATION OF 1,5-DIAMINONAPHTHALINES
MXPA04001856A (es) Indan-1-oles c2-sustituidos y sus derivados, metodo para su produccion y su uso como medicamentos.
MXPA04001852A (es) Uso de sistemas indan-1-ol c2-sustituidas para la produccion de medicamentos para la profilaxis o tratamiento de obesidad.
TW200407314A (en) Preparation of 4, 6-dichloro-5-fluoropyrimidine
MXPA04001846A (es) Indan-1-onas c2-substituidas y sus derivados, metodos para su produccion y su uso como medicamentos.